The bipartisan ASAP Act creates a pathway for Medicare coverage of FDA‑approved blood tests

A simple blood test can now detect Alzheimer’s before symptoms appear — a scientific milestone that could change lives. As a caregiver to my mom, Anne, who had early-onset Alzheimer’s Disease and died in 2015, I am now in my mid-40s with two young children of my own and I want the ability to know my predisposition to the disease so I can have a chance to live a full life with my family and prepare accordingly for our future together.

The bipartisan ASAP Act creates a pathway for Medicare coverage of FDA‑approved blood tests that detect Alzheimer’s biomarkers — tests that provide a simpler, more scalable approach than previous diagnostic pathways. This is a “mammogram moment” for Alzheimer’s — just as Congress enabled Medicare to cover routine mammograms, leading to earlier detection and declining breast cancer deaths, Congress can deliver the same breakthrough moment for Alzheimer’s.

Please join me and the Alzheimer’s Association in thanking Congresswoman Jan Schakowsky (IL-09) for cosponsoring the bipartisan Alzheimer’s Screening and Prevention (ASAP) Act, and ask her to tell congressional leadership to move this bill ASAP! We need everyone’s voice to make this possible. To learn more about this disease and how you can join the fight to end Alzheimer’s, visit alz.org.